PT  - JOURNAL ARTICLE
AU  - Robert D.  Inman
AU  - Denis Choquette
AU  - Majed Khraishi
AU  - Dafna Gladman
AU  - Shamiza Hussein
AU  - Drew Neish
AU  - Patrick Leclerc
TI  - Real-world Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results from the CanSpA Research Network
AID  - 10.3899/jrheum.220824
DP  - 2023 Jan 15
TA  - The Journal of Rheumatology
PG  - jrheum.220824
4099  - http://www.jrheum.org/content/early/2023/01/10/jrheum.220824.short
4100  - http://www.jrheum.org/content/early/2023/01/10/jrheum.220824.full
AB  - Objective Axial spondyloarthritis (axSpA) is a chronic, immune-mediated, inflammatory condition consisting of two clinical subsets: non-radiographic axSpA (nr-axSpA) and ankylosing spondylitis (AS), the latter having an estimated prevalence of 0.2 to 1% in Canada. Secukinumab received Health Canada approval in 2016 for the treatment of adults with axSpA who have responded inadequately to conventional treatment, and has demonstrated efficacy and safety through extensive clinical trials. However, there is limited evidence on its real-world use in Canada. The objective of this study was to use the Canadian Spondyloarthritis (CanSpA) Research Network to describe real-world retention and effectiveness of secukinumab in the Canadian axSpA population. Methods This was an observational cohort study of Canadian axSpA patients ages 18-65 years within the CanSpA network that had received treatment with secukinumab. Patients were indexed on first date of secukinumab initiation. Retention and clinical effectiveness were assessed at 12-months post-index. Clinical effectiveness was measured as proportion in remission and change in disease activity using multiple clinical indices. Results 146 patients were included. Overall retention was estimated at 62.9%. Low disease activity (BASDAI <4) was achieved in 29.2% of patients, and 2.0% had achieved ASDAS-based remission. BASMI scores improved by >60% from baseline to 12-months. Conclusion The results of this real-world study of Canadian axSpA patients, one of the first of its kind, support the effectiveness of secukinumab for treatment of axSpA. The CanSpA network presents an opportunity to continue building and improving the real-world evidence base for treatment of Canadian patients with SpA.